Details of the Drug

General Information of Drug (ID: DMGRKDC)

Drug Name

Taniraleucel

Indication

Disease Entry	ICD 11	Status	REF
Malignant glioma	2A00.0	Phase 1/2	[1]
------------------------------------------------------------------------------------

Drug Type

Cell therapy

Cross-matching ID

References

1	ClinicalTrials.gov (NCT05218408) A Phase I/IIa Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001in Combination With Recombinant Human Interleukin-2 in Adults With Recurrent Resection Eligible IDH1 Wild-type Glioblastoma. U.S.National Institutes of Health.